Dr. Gail Roboz Interviewed on Good Morning America about Myelodysplastic Syndrome
Posted: August 31, 2012 Filed under: Leukemia News, Physician Presentations | Tags: Blood Disorders, Gail Roboz, Gail Roboz MD, MDS, Myelodysplastic Syndrome, New York Presbyterian, Weill Cornell Medical College Comments Off on Dr. Gail Roboz Interviewed on Good Morning America about Myelodysplastic Syndrome
To view the video, click here.
Dr. Gail Roboz speaks to ABC World News about MDS
Posted: August 31, 2012 Filed under: Leukemia News, Physician Presentations, Uncategorized | Tags: Blood Disorders, Gail Roboz, Gail Roboz MD, MDS, Myelodysplastic Syndrome, Weill Cornell Comments Off on Dr. Gail Roboz speaks to ABC World News about MDS
To see the interview, click here.
Leukemia & Lymphoma Society Awards $1.8 Million to Weill Cornell for Translational Research in Blood Cancers
Posted: August 31, 2012 Filed under: Accolades, Laboratory Research, Leukemia News | Tags: Blood Disorders, Leukemia, Leukemia Treatment, New York Presbyterian, Weill Cornell Comments Off on Leukemia & Lymphoma Society Awards $1.8 Million to Weill Cornell for Translational Research in Blood CancersNew Translational Rese
arch Grants Awarded to Accelerate Promising Blood Cancer Research Discoveries from the Laboratory to the Patients’ Bedside. Read the press release here.
For more information on the Leukemia and Lymphoma Society, click here.
For information on the Guzman Lab and the research of Monica Guzman, PhD, click here.
For information on the laboratory of Dr. Duane Hassane, click here.
Weill Cornell Medical College Selected to Join New MDS Clinical Research Consortium
Posted: June 19, 2012 Filed under: Clinical Trials, Laboratory Research, Leukemia News | Tags: Gail Roboz, Gail Roboz MD, MDS, Myelodysplastic Syndrome, Weill Cornell, Weill Cornell Medical College Comments Off on Weill Cornell Medical College Selected to Join New MDS Clinical Research Consortium
Weill Cornell Among Centers Participating in Myelodysplastic Syndrome Research Consortium
Posted: June 12, 2012 Filed under: Leukemia News | Tags: Myelodysplastic Syndrome, Weill Cornell Leukemia Program Leave a commentSix academic medical centers, including Weill Cornell Medical College, have set up the first privately funded consortium in the US to focus on clinical trials and research for patients with myelodysplastic syndrome (MDS).
The MDS Clinical Research Consortium is a five-year, $16 million initiative sponsored by the Aplastic Anemia & MDS International Foundation and supported by the Edward P Evans Foundation.
By joining forces, the centers hope to achieve a ‘critical mass’ of dedicated institutions that can support the evaluation of promising new MDS therapies as well as epidemiological and translational studies leading to new treatments and classifications for the disease.
The participating centers are Weill Cornell Medical College, Taussig Cancer Institute at Cleveland Clinic; Dana Farber Cancer Institute; MD Anderson Cancer Center; H Lee Moffitt Cancer Center and Research Institute, and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Leukemia Program Director, Gail Roboz, Interviewed on CNN’s “The Situation Room”
Posted: June 12, 2012 Filed under: Leukemia News, Physician Presentations, Uncategorized | Tags: Blood Disorders, Gail Roboz, Gail Roboz MD, MDS, Weill Cornell Comments Off on Leukemia Program Director, Gail Roboz, Interviewed on CNN’s “The Situation Room”Dr. Roboz describes the symptoms and treatment of Myelodysplastic Syndrome. Click the image to view her interview.
New Clinical Trial: Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Posted: March 26, 2012 Filed under: Clinical Trials, Leukemia News | Tags: Acute Myeloid Leukemia, AML, blood cancer treatment, chemotherapy, Core Binding Factor Abnormality, dasatinib, Gail Roboz MD, NewYork Presbyterian Hospital, Weill Cornell Medical College Leave a commentThe Weill Cornell Leukemia Program is now recruiting patients for a new study, “CALGB 10801: A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib and Continuation Therapy with Dasatinib Alone in Newly Diagnosed Patients with Core Binding Factor Acute Myeloid Leukemia (AML).”
The physician leading the study at Weill Cornell is Gail Roboz, MD. For more information or to see if you are eligible for the study, please contact Tania Curcio, RN at (212) 746-2571 or email Tania at tjc9003@med.cornell.edu.
Study details:
This is a clinical trial for patients with acute myeloid leukemia (AML) that possesses an abnormal molecular feature (a gene mutation). The purpose of this study is to test the safety and effectiveness of adding the drug dasatinib to a treatment regimen in patients with AML and to determine how well the leukemia responds to the treatment. The study is being done because currently available treatment is not effective in curing patients with this type of leukemia.
There are three parts to the treatment in this study. The first part of the therapy will test the safety and effectiveness of adding dasatinib to the standard combination of chemotherapy drugs used to treat AML that include daunorubicin and cytarabine. The second part of the therapy will test the safety and effectiveness of combining dasatinib with another chemotherapy treatment, consolidation therapy with high-dose cytarabine. Finally, the third part of the therapy will test the effectiveness of the use of dasatinib alone for 12 months during continuation therapy.
Patients will receive therapy for about 18 months on study. After you are finished with the therapy, you will be asked to visit the office for follow-up at least every 2 months for 2 years, then every 3 months for 2 years, then yearly for a maximum of 10 years from when you entered the study.
Key Eligibility
- Men and women age 18 and older
- Acute myeloid leukemia (AML with Core Binding Factor (CBF) abnormality
- No prior chemotherapy for leukemia or myelodysplasia
- Detailed eligibility reviewed when you contact the study team
Dr. Roboz Speaks on Genomics in AML
Posted: January 18, 2012 Filed under: Laboratory Research, Leukemia News, Patient Education, Physician Presentations | Tags: Acute Myeloid Leukemia, AML, Blood Disorders, cancer treatment, Gail Roboz, Gail Roboz MD, Leukemia, Leukemia Treatment Comments Off on Dr. Roboz Speaks on Genomics in AMLDr. Gail Roboz spoke with ecancertv at ASH 2011 in San Diego about the major genomic research on acute myeloid leukaemia. There has been a lot of recent success on identifying mutations and abnormalities in AML; however, Prof Roboz believes that the discovery period with genomic research is coming to an end and a move towards clinical trials and targeted therapies need to be developed. The largest development has been the role of stems cell in research and how to target the cells that are left over after chemotherapy.
THE INSIDE STORY: Why a New Day Is Dawning for Personalized Cancer Treatments
Posted: October 18, 2011 Filed under: Laboratory Research, Leukemia News, Uncategorized | Tags: Ari Melnick, cancer treatment, Weill Cornell, Weill Cornell Medical College Comments Off on THE INSIDE STORY: Why a New Day Is Dawning for Personalized Cancer Treatments
Check out Dr. Melnick on YouTube describing his experience at Weill Cornell.
Oral Chemotherapy Bill Signed Into Law in New York State
Posted: October 3, 2011 Filed under: Leukemia News | Tags: cancer treatment, Gail Roboz MD, health insurance, Leukemia Treatment, oral chemotherapy, Weill Cornell Medical College Comments Off on Oral Chemotherapy Bill Signed Into Law in New York StateOn September 23 New York Governor Andrew Cuomo signed into law a bill that requires health plans to cover orally administered chemotherapy treatments at a cost equal to intravenously or injected chemotherapy treatments. The bill will go into effect January 2012.
Traditional intravenous chemotherapy drugs administered in a hospital or clinic are often included as a medical benefit under a patient’s health insurance plan. However, many oral chemotherapies are defined as a prescription benefit and frequently require much higher out-of-pocket costs for patients, or they have been unavailable to patients with financial caps on their prescription benefit.
“Many of our patients with leukemia and bone marrow disorders will directly benefit from this important new bill,” said Dr. Gail J. Roboz, Director of the Weill Cornell Leukemia Program. ” I am so proud that one of my patients was instrumental in this important accomplishment.”
Weill Cornell Leukemia Program 